Stago Launches Products For Measurement Of Rivaroxaban
The STA – Rivaroxaban Calibrator and Controls are highly specific, automation-ready products for determining the rivaroxaban concentration in plasma when used in conjunction with the STA - Liquid Anti-Xa assay. This method was shown to have favorable performance with respect to its linearity and coefficient of variation (CV) in a recent publication.1
Rivaroxaban (Xarelto), a synthetically derived drug from Janssen Pharmaceuticals and Bayer Healthcare, inhibits the blood coagulation cascade by its inhibitory action on coagulation factor Xa, resulting in inhibition of fibrin clot formation.2
The STA – Rivaroxaban Calibrator (catalog # 00704US) and Control (catalog # 00706US) products contain two levels of control at the low and high end of the calibrator range. Both the calibrator and control are stable for 8 hours on board the STA-R Evolution Expert Series and STA Compact automated coagulation analyzers. Utilization of STA – Rivaroxaban Calibrator and Controls ensures high specificity and precision for rivaroxaban determination. In addition, barcoding of critical information on the reagent vials prevents transcription errors.
The rivaroxaban controls and calibrators are labeled for research use only, and are not for use in diagnostic procedures in the United States and Canada.
About Diagnostica Stago, Inc.
Diagnostica Stago, Inc. is the exclusive provider of the Diagnostica Stago Hemostasis product lines in the United States and offers a complete system of coagulation instruments and optimized reagent kits for research as well as for routine analysis. Diagnostica Stago, Inc. is the U.S. subsidiary of Diagnostica Stago, S.A.S. France, a leader in the development and manufacture of Hemostasis products. For more information, visit www.stago-us.com.
- Harenberg et al., Semin Thromb Hemost. 38, (2012) 178-184.
- Samama, Thromb Res. 127, (2011) 497-504.
SOURCE: Diagnostica Stago, Inc.